The Food and Drug Administration (FDA) has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years. 

The effectiveness of Gardasil 9 against oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, was based on the effectiveness of Gardasil and Gardasil 9 to prevent anogenital disease caused by HPV types covered by the vaccine. Continued approval of this indication may be contingent upon ongoing confirmatory trial results.

Gardasil 9 is also indicated for use:

  • In females aged 9 to 45 years for the prevention of cervical, vulvar, vaginal, and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
  • In males aged 9 to 45 years for the prevention of anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

Patients who receive the vaccine should still undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers when clinically indicated.


Continue Reading

Related Articles

Gardasil 9 is supplied as a suspension for intramuscular administration in 0.5mL single-dose vials and prefilled syringes.

For more information visit merck.com.

This article originally appeared on MPR